Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (NQ:KNSA)

30.47 +3.43 (+12.68%)
Streaming Delayed Price Updated: 3:04 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease – 
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) Near the Top of Equities by Percentage Gain on 7/25
Via Investor Brand Network
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.